Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Assets (2023 - 2025)

Historic Assets for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $190.8 million.

  • Contineum Therapeutics' Assets fell 1165.88% to $190.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.8 million, marking a year-over-year decrease of 1165.88%. This contributed to the annual value of $212.8 million for FY2024, which is 6324.38% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Assets of $190.8 million as of Q3 2025, which was down 1165.88% from $182.9 million recorded in Q2 2025.
  • Contineum Therapeutics' 5-year Assets high stood at $221.4 million for Q2 2024, and its period low was $123.6 million during Q1 2024.
  • Moreover, its 3-year median value for Assets was $194.6 million (2025), whereas its average is $184.5 million.
  • As far as peak fluctuations go, Contineum Therapeutics' Assets surged by 6324.38% in 2024, and later crashed by 1737.8% in 2025.
  • Contineum Therapeutics' Assets (Quarter) stood at $130.4 million in 2023, then skyrocketed by 63.24% to $212.8 million in 2024, then dropped by 10.34% to $190.8 million in 2025.
  • Its Assets stands at $190.8 million for Q3 2025, versus $182.9 million for Q2 2025 and $198.3 million for Q1 2025.